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Solutions to Optimize Patient
Recruitment in Inflammatory
Bowel Disease TrialsDear Editors,
We read with great interest the article by Harris et al1
reporting the Competition for Clinical Trials in Inflammatory
Bowel Diseases. The authors provide an alarming overview of
the situation,with adecrease in the last 20years (1998–2018)of
the average recruitment rate from 0.32 to 0.13 patients per site
per month in moderate-to-severe ulcerative colitis, and from
0.65 to 0.1 in moderate to severe Crohn’s disease. They present
an in-depth analysis of the causes of this scourge and propose
innovative solutions to try toovercome it, aswell as openingnew
centers in new countries. However, this last point will further
spread the problem and increase the already astronomical cost
of clinical trials for inflammatory bowel disease (IBD). In addi-
tion, their proposals mainly focus on the level of complexity of
the studies, whereas it is well-known that there are 3 others
bottlenecks in patient recruitment in clinical trials, at the level of
the patient, the doctor, and the participating center.2
As a national study group in IBD, the GETAID (Groupe Etude
Therapeutique des Affections Inflammatoires Digestives) was
previously threatenedofbankruptcywhen itwas confronted toa
lower than expected recruitment rate for a major trial we
accepted to promote.3 Considering that, as a physician, it is very
challenging to be aware of all ongoing trials on-site, to precisely
know inclusion and exclusion criteria for these trials, and to find
time available for recruitment tasks, we developed the CT-Scout
solution, a multidevice web application that aims to optimize
patient recruitment by enabling all physicians from one center,
including noninvestigators, to identify potentially eligible pa-
tients. Identifying these patient, in real time, by answering a
simple and short questions in just a few clicks, allows physicians
to checkwhether thepatientmatcheswith anongoing computed
tomography (CT) scans on site and, in that case, to send a noti-
fication to the research team, which takes over the recruitment
process.4 Importantly, this solution, customized per site and
including potentially all active trials, provides real-time data on
recruitment in each site, increasing the visibility for all stake-
holders from detection to randomization.
We recently conducted a study aiming to compare the
number of patients enrolled in 2 phase III clinical trials
HICKORY5 and BERGAMOT6 evaluating the efficacy and
safety of etrolizumab in ulcerative colitis and Crohn’s dis-
ease in sites equipped or not with CT-Scout.7 These results
were presented as an oral communication during the United
European Gastroenterology Week in 2019. Briefly, it was a
multicenter, prospective, open-label, observational study
including all sites opened for >6 months. Recruitment fig-
ures were provided by the sponsor, which considered all
French sites equipped with CT-Scout and sites in othercountries not equipped with CT-Scout at the time of study
launch. The primary endpoint was the mean number of
patients randomized per site in both studies. Secondary
endpoints were the mean number of patients randomized in
each study. Patients who signed informed consent form
(screened) and those finally randomized were compared in
sites equipped or not with CT-Scout using a 1-way analysis
of variance followed by post hoc Tukey and Mann-Whitney
tests. During the observational period of 40 months
(September 2015 to December 2018), 644 and 289 patients
were screened and randomized in 134 sites in both trials,
respectively. Twenty-one sites in France were equipped
with CT-Scout and were compared with the 113 sites non-
equipped with the app, located in Belgium (n ¼ 14), Ger-
many (n ¼ 41), Spain (n ¼ 19), the UK (n ¼ 26), and Israel
(n ¼ 13). There were 307 and 149 patients in 78 sites for
Hickory, and 337 and 140 patients for Bergamot in 102
sites. The mean number of patients screened and random-
ized per site in sites equipped and nonequipped in both
studies was 7.55 and 3.05 (P < .001) and 3.79 and 1.27 (P <
.001), respectively. For Hickory, they were 9.17 and 3.14
(P < .001) and 5.17 and 1.28 (P < .001), respectively. For
Bergamot, they were 5.94 and 2.97 (P ¼ .003) and 2.41 and
1.26 (P ¼ .009), respectively. The mean number of patients
detected and selected with the app was 13.9 and 15.9 and
9.2 and 5.9, for Hickory and Bergamot, respectively. So, the
switch from prescreened to screened patients was lower in
Bergamot, raising interesting questions that need to be
addressed, and in phase with the results reported by Harris
et al.1 We therefore demonstrated a significant increase in
patient recruitment in IBD clinical trials, with randomization
rates 2–4 times higher in equipped sites compared with
nonequipped ones.
We work therefore on a similar platform accessible from
patients’ association web-site (Totem4me) giving to each pa-
tient the opportunity to test himself and in case of matching,
to be referenced to a site having the ongoing recruitment trial
using geolocation. Based on these findings, we believe that
such innovative solutions should be extended worldwide to
contribute to solve the challenging issue of insufficient patient
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thoughtful comments and contributions to
recruitment in inflammatory bowel disease clinicaltrial. The innovative approach is one of the many that will
be needed to tackle the challenges facing this area, and we
welcome others.
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Learning Model That Out-
performs Clinical Risk Scoring
Systems for Upper Gastroin-
testinal BleedingDear Editors,
We read with interest the article titled “Validation of a
Machine Learning Model That Outperforms Clinical Risk
Scoring Systems for Upper Gastrointestinal Bleeding” by
Shung et al1 published in the January issue of the Journal.
The authors concluded that the machine learning model had
a greater area under the curve and had higher levels of
specificity at 100% sensitivity in comparison to other risk
scoring systems such as the Glasgow-Blatchford score,
admission Rockall score, and AIMS65 score. However, we
would like to ask the authors for clarification of the external
validation set (n ¼ 800) that is mentioned in the visual
abstract and discussion.
The article explained that the dataset was separated into
the training set (n ¼ 1958) and the external validation set
(n ¼ 399). The external validation set is also known as the
testing dataset, which is designed for testing the final ma-
chine learning model on an independent dataset to assess
the performance, accuracy, and generalizability of the ma-
chine learning model.2 Although the authors clearly stated
in the Methods that the external validation was performed
on the external validation sample of 399 cases, the visual
abstract showed the performance of the machine learning
model and the Glasgow-Blatchford score model tested in
800 patients. Hence, it is important to clarify whether this
dataset of 800 patients represents a different dataset used
for external validation than the one described in the
Methods and Results. Our concern is that the external
validation size of 800 patients may represent the testing
dataset and a portion of the training dataset. By using the
dataset that machine learning model has already learned
for testing its predictive performance, the machine learning
model will have almost the perfect chance of making the
correct prediction, which will create a bias toward better
performance.
We would respectfully ask the authors to clarify the
number shown in the visual abstract and discussion. In case
that the dataset used for external validation is a separate
